[
  {
    "pmid": "36455187",
    "citation": "{'name': 'Itzykson R', 'authtype': 'Author', 'clusterid': ''} et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023 Apr 1)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": 10.3,
    "overall_survival_median": 21.9,
    "total_patients": 170,
    "cmml_patients": null,
    "supporting_quotes": [
      "One-hundred seventy patients received DAC (n = 84) or HY (n = 86).",
      "With a median follow-up of 17.5 months, median EFS was 12.1 months in the DAC arm and 10.3 months in the HY arm (hazard ratio [HR], 0.83; 95% CI, 0.59 to 1.16; P = .27).",
      "Compared with HY, DAC significantly reduced the risk of CMML progression or transformation to acute myelomonocytic leukemia (cause-specific HR, 0.62; 95% CI, 0.41 to 0.94; P = .005) at the expense of death without progression or transformation (cause-specific HR, 1.55; 95% CI, 0.82 to 2.9; P = .04).",
      "Median overall survival was 18.4 months in the DAC arm and 21.9 months in the HY arm (P = .67).",
      "Compared with HY, DAC significantly reduced the risk of CMML progression or transformation to acute myelomonocytic leukemia (cause-specific HR, 0.62; 95% CI, 0.41 to 0.94; P = .005) at the expense of death without progression or transformation (cause-specific HR, 1.55; 95% CI, 0.82 to 2.9; P = .04).",
      "Thirty (35%) HY patients (P = .0004)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In this study comparing decitabine and hydroxyurea for advanced CMML, hydroxyurea demonstrated an overall response rate of 35%, a median overall survival of 21.9 months, and a median event-free survival of 10.3 months.  The study notes that decitabine showed a superior response rate, but overall survival was not significantly different.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26666606",
    "citation": "{'name': 'Imai H', 'authtype': 'Author', 'clusterid': ''} et al. Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case.. Internal medicine (Tokyo, Japan) (2015)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26666606/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "We describe the case of an 85-year-old man diagnosed with chronic myelomonocytic leukemia whose disease was treated with hydroxyurea for 3 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study only presents a single case study of a CMML patient treated with hydroxyurea.  No response rates or survival data are provided. The patient developed severe pneumonitis and died after 3 months of treatment.  Therefore, no meaningful efficacy data is available.",
    "has_efficacy_data": false
  },
  {
    "pmid": "8839839",
    "citation": "{'name': 'Wattel E', 'authtype': 'Author', 'clusterid': ''} et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Fran\u00e7ais des My\u00e9lodysplasies and European CMML Group.. Blood (1996 Oct 1)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8839839/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 60.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 20.0,
    "total_patients": 105,
    "cmml_patients": 105,
    "supporting_quotes": [
      "Response to treatment was seen in 60% of the pts in the HY group, versus 36%, respectively, in the VP16 group (P = .02).",
      "Median actuarial survival was 20 months in the HY arm, versus 9 months in the VP16 arm (P < 10(-4)).",
      "The study was closed on first interim analysis that showed a superiority of HY over VP16, after inclusion of 105 pts (HY arm: 53, VP16 arm: 52)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Hydroxyurea demonstrated a 60% overall response rate and a median overall survival of 20 months in patients with advanced CMML.  This was significantly better than the VP16 arm.",
    "has_efficacy_data": true
  },
  {
    "pmid": "2052066",
    "citation": "{'name': 'Wolff-Kormann PG', 'authtype': 'Author', 'clusterid': ''} et al. Successful treatment with hydroxyurea of ocular involvement in chronic myelomonocytic leukemia.. The New England journal of medicine (1991 Jul 18)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/2052066/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [],
    "data_source_location": "Extraction failed",
    "extraction_confidence": null,
    "efficacy_summary": "504 Deadline Exceeded",
    "has_efficacy_data": false
  },
  {
    "pmid": "9088933",
    "citation": "{'name': 'Liozon E', 'authtype': 'Author', 'clusterid': ''} et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.. Hematology and cell therapy (1997 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9088933/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 21,
    "total_patients": 58,
    "cmml_patients": 1,
    "supporting_quotes": [
      "From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients.",
      "Three patients who were continuously receiving HU had a leukemic transformation after a chronic phase of respectively 47, 81 and 90 months.",
      "the third patient developed a chronic myelomonocytic leukemia (CMML) and is alive at 21 months"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports on three patients with essential thrombocythemia who developed leukemic transformation while receiving hydroxyurea. One of these transformations was to CMML, with the patient surviving 21 months after diagnosis.  No response rates or PFS data is provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "3113160",
    "citation": "{'name': 'von Eyben FE', 'authtype': 'Author', 'clusterid': ''} et al. High-voltage irradiation and hydroxyurea for pulmonary leukostasis in acute myelomonocytic leukemia.. Acta haematologica (1987)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/3113160/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 0,
    "supporting_quotes": [
      "A 29-year-old man with acute myelomonocytic leukemia had an initial leukocyte count of 192 X 10(9) cells/l and 84% blasts."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The abstract describes a single case of acute myelomonocytic leukemia (AML), not CMML, treated with hydroxyurea.  Pulmonary leukostasis developed, which responded to radiation. No response rates or survival data for hydroxyurea treatment in CMML are provided.",
    "has_efficacy_data": false
  },
  {
    "pmid": "12708945",
    "citation": "{'name': 'Seki JT', 'authtype': 'Author', 'clusterid': ''} et al. Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia.. The Annals of pharmacotherapy (2003 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/12708945/",
    "drug": "hydroxyurea",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 0,
    "supporting_quotes": [
      "To report 2 cases of acute tumor lysis syndrome (ATLS) associated with hydroxyurea treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study reports two cases of acute tumor lysis syndrome (ATLS) in patients treated with hydroxyurea, one with acute lymphocytic leukemia and one with acute myeloid leukemia.  No efficacy data (response rates or survival) for hydroxyurea in CMML is provided.",
    "has_efficacy_data": false
  }
]